HLA-E expression and its clinical relevance in human renal cell carcinoma
暂无分享,去创建一个
B. Seliger | A. Hartmann | C. Stoehr | H. Taubert | S. Wach | B. Wullich | D. Quandt | Simon Jasinski-Bergner | J. Bukur | W. Legal
[1] S. H. van der Burg,et al. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma , 2015, Oncotarget.
[2] T. Whiteside. Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV , 2015, Cancer Microenvironment.
[3] R. Blasczyk,et al. The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch , 2015, Immunogenetics.
[4] P. Terasaki,et al. Immunobiology of HLA Class-Ib Molecules in Transplantation , 2015 .
[5] M. Donia,et al. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.
[6] Camilla Sampaoli,et al. Monoclonal antibodies to HLA‐E bind epitopes carried by unfolded β2m‐free heavy chains , 2015, European journal of immunology.
[7] B. Seliger,et al. Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis , 2015, Oncoimmunology.
[8] P. Terasaki,et al. The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes. , 2015, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[9] M. Sznol,et al. Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. , 2015, Seminars in oncology.
[10] M. Tilanus,et al. Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype. , 2015, Tissue antigens.
[11] E. Tartour,et al. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma , 2015, Oncoimmunology.
[12] B. Seliger,et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma , 2015, Oncoimmunology.
[13] B. Seliger,et al. Immune signature of tumor infiltrating immune cells in renal cancer , 2015, Oncoimmunology.
[14] Q. Tao,et al. Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. , 2014, Cancer letters.
[15] B. Seliger,et al. Identification of 14-3-3β Gene as a Novel miR-152 Target Using a Proteome-based Approach* , 2014, The Journal of Biological Chemistry.
[16] H. Putter,et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study , 2014, BMC Cancer.
[17] B. Seliger,et al. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation , 2014, Journal of Translational Medicine.
[18] P. Terasaki,et al. Gastric cancer progression may involve a shift in HLA‐E profile from an intact heterodimer to β2‐microglobulin‐free monomer , 2014, International journal of cancer.
[19] P. Kuppen,et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients , 2013, British Journal of Cancer.
[20] F. Dallocchio,et al. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding , 2013, Molecular and Cellular Biochemistry.
[21] You-jian He,et al. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer , 2013, Medical Oncology.
[22] Pieter Wesseling,et al. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells , 2013, Immunology.
[23] Longmei Zhao,et al. Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. , 2012, Human immunology.
[24] B. Seliger,et al. The role of classical and non-classical HLA class I antigens in human tumors. , 2012, Seminars in cancer biology.
[25] Hong Jiang,et al. Human leukocyte antigen E in human cytomegalovirus infection: friend or foe? , 2012, Acta biochimica et biophysica Sinica.
[26] A. Poprach,et al. HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma , 2012, Diagnostic Pathology.
[27] E. Carosella,et al. The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. , 2011, Blood.
[28] E. Donadi,et al. Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. , 2011, Histology and histopathology.
[29] P. Natali,et al. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. , 2011, Neoplasia.
[30] B. Seliger,et al. Monitoring peri-operative immune suppression in renal cancer patients. , 2011, Oncology reports.
[31] Federica Cavallo,et al. 2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.
[32] F. Marincola,et al. Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines , 2011, Clinical Cancer Research.
[33] H. Putter,et al. HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.
[34] J. Casanova,et al. A novel form of cell type-specific partial IFN-gammaR1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. , 2010, Human molecular genetics.
[35] X. Zhang,et al. Characterization of HLA-G expression in renal cell carcinoma. , 2009, Tissue antigens.
[36] P. Debré,et al. HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT , 2009, Bone Marrow Transplantation.
[37] B. Seliger,et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. , 2008, Tissue antigens.
[38] S. Hirohashi,et al. Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.
[39] A. Moreau,et al. Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.
[40] B. Seliger,et al. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? , 2004, The Journal of urology.
[41] B. Seliger,et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.
[42] W. Ferlin,et al. Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells. , 2003, Trends in immunology.
[43] Hein Putter,et al. Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.
[44] K. Wright,et al. Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line , 2000 .
[45] D. Speiser,et al. CD28‐negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients , 1999, European journal of immunology.
[46] F. Garrido,et al. Expression of HLA G in human tumors is not a frequent event , 1999, International journal of cancer.
[47] B. Seliger,et al. Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer , 1999, International journal of cancer.
[48] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[49] D. Goodlett,et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. , 1998, Journal of immunology.
[50] J. Coligan,et al. Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis , 1998, The Journal of experimental medicine.
[51] J. Bell,et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.
[52] B. Seliger,et al. Analysis of the MHC Class I Antigen Presentation Machinery in Human Embryonal Carcinomas: Evidence for Deficiencies in TAP, LMP and MHC Class I Expression and their Upregulation by IFN‐γ , 1997, Scandinavian journal of immunology.
[53] Fan Yang,et al. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. , 2015, Cellular immunology.
[54] I. Ellis,et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.
[55] G. Ferrara,et al. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. , 2005, Human immunology.